In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide

Drug Development and Industrial Pharmacy

Volumn 31, Issue 7, 2005, Pages 677-685

  Defang, Ouyang ^a   Shufang, Nie ^a   Wei, Li ^a   Hong, Guo ^b   Hui, Liu ^c   Weisan, Pan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b JIAMUSI UNIVERSITY   (China)

^c WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Bilayer matrix tablets; Elementary osmotic pump; Extended release; Glipizide; In vitro in vivo correlation; Metformin

Indexed keywords

ACETONE; CELLULOSE ACETATE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MACROGOL; MAGNESIUM STEARATE; METFORMIN; POLYMER; POVIDONE; SODIUM CARBONATE; STEARIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ASTHMA; BILAYER HYDROPHILIC MATRIX TABLET; CHRONIC DISEASE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOG; DRUG ABSORPTION; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; ELEMENTARY OSMOTIC PUMP TABLET; EXTENDED DRUG RELEASE; HEART DISEASE; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PH; TABLET;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOGS; DRUG COMBINATIONS; GLIPIZIDE; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; METFORMIN; OSMOSIS; SOLUBILITY; TABLETS;

EID: 25144436313     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500216410     Document Type: Article

References (10)

1. Balan, G., Timmins, P., Greene, D. S., Marathe, P. H. (2001). In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. Journal of Pharmaceutical Sciences, 90, 1176-1185.
2. Carruthers, S. G., et al. (2000). Clinical Pharmacology (4th ed.). Beijing: McGraw-Hill, 529-551.
3. Gan, Y., Pan, W., Wei, M., & Zhang, R. (2002). Cyclodextrin complex osmotic tablet for GZ delivery. Drug Development and Industrial Pharmacy, 28, 1015-1021.
4. Katzung, B. G. (2001). Basic and Clinical Pharmacology (8th ed.). Beijing: McGraw-Hill, 711-734.
5. Matharu, et al. (2003). Pharmaceutical Composition. US Patent 20030021841 2003-01-30.
6. Scheen, A. J. (1996). Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 30, 359-371.
7. Schug, B. S., Brendel, E., Wolf, D., Wonnemann, M., Wargenau, M., Blume, H. H. (2002). Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. European Journal of Pharmaceutical Sciences, 15, 279-285.
8. U.S. Department of Health and Human Services (1997). Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlation. Rockville, MD: Center for Drug Evaluation and Research (CDER).
9. Verma, & Garg (2004). Development and evaluation of osmotically controlled oral drug delivery system of glipizide. European Journal of Pharmaceutics and Biopharmaceutics, 57, 513-525.
10. Vidon, N., et al. (1988). Metformin in the digestive tract. Diabetes Research and Clinical Practice, 4, 223-229.